miR-24 regulates p27 expression in prostate cancer

Seodhna Lynch, Michael McKenna, Colum Walsh, Declan McKenna

Research output: Contribution to journalArticle

Abstract

MicroRNAs (miRNAs) are small, non-coding RNA molecules with an important role in cancer. In prostate cancer, several miRNAs are expressed abnormally suggesting they may be useful markers for diagnosis, prognosis, and potential therapeutic intervention in this disease. In this study we used PCR to investigate the expression of miR-24 in a panel of prostate cancer cell-lines and in a series of clinical prostate biopsy specimens. The biological significance of miR-24 expression in prostate cancer cells was assessed by a series of in vitro bioassays and the effect on proposed targets p27 (CDKN1B) and p16 (CDK2NA) was investigated. We showed that miR-24 expression was significantly lower in prostate cancer cell lines compared to a normal prostate epithelial cell line. Decreased expression of miR-24 was also more frequently observed in both needle core and prostatectomy tumour tissue relative to matched normal tissue. Low miR-24 expression correlated with high PSA serum levels and other markers of increased prostate cancer progression. Importantly, over-expression of miR-24 inhibited cell cycle, proliferation, migration and clonogenic potential of prostate cancer cells, as well as inducing apoptosis. p27 and p16 were confirmed as targets of miR-24 in prostate cancer cells and a significant inverse correlation between miR-24 and p27 was revealed in clinical prostatectomy specimens. These findings provide evidence that miR-24 has a tumour suppressor role in prostate cancer and also targets p27 and p16 in prostate cancer cells. We propose that it may be a useful progression biomarker or focus of therapeutic intervention for this disease.
LanguageEnglish
Pages208-209
JournalUlster Medical Journal
Volume84
Issue number3
Publication statusPublished - Oct 2015

Fingerprint

Prostatic Neoplasms
Prostatectomy
MicroRNAs
Cell Line
Prostate
Small Untranslated RNA
Neoplasms
Biological Assay
Needles
Cell Cycle
Biomarkers
Epithelial Cells
Cell Proliferation
Apoptosis
Biopsy
Polymerase Chain Reaction
Therapeutics
Serum

Keywords

  • miR-24
  • p27
  • prostate cancer

Cite this

Lynch, Seodhna ; McKenna, Michael ; Walsh, Colum ; McKenna, Declan. / miR-24 regulates p27 expression in prostate cancer. In: Ulster Medical Journal. 2015 ; Vol. 84, No. 3. pp. 208-209.
@article{5a6b848430fc4a169fb496c9e1571416,
title = "miR-24 regulates p27 expression in prostate cancer",
abstract = "MicroRNAs (miRNAs) are small, non-coding RNA molecules with an important role in cancer. In prostate cancer, several miRNAs are expressed abnormally suggesting they may be useful markers for diagnosis, prognosis, and potential therapeutic intervention in this disease. In this study we used PCR to investigate the expression of miR-24 in a panel of prostate cancer cell-lines and in a series of clinical prostate biopsy specimens. The biological significance of miR-24 expression in prostate cancer cells was assessed by a series of in vitro bioassays and the effect on proposed targets p27 (CDKN1B) and p16 (CDK2NA) was investigated. We showed that miR-24 expression was significantly lower in prostate cancer cell lines compared to a normal prostate epithelial cell line. Decreased expression of miR-24 was also more frequently observed in both needle core and prostatectomy tumour tissue relative to matched normal tissue. Low miR-24 expression correlated with high PSA serum levels and other markers of increased prostate cancer progression. Importantly, over-expression of miR-24 inhibited cell cycle, proliferation, migration and clonogenic potential of prostate cancer cells, as well as inducing apoptosis. p27 and p16 were confirmed as targets of miR-24 in prostate cancer cells and a significant inverse correlation between miR-24 and p27 was revealed in clinical prostatectomy specimens. These findings provide evidence that miR-24 has a tumour suppressor role in prostate cancer and also targets p27 and p16 in prostate cancer cells. We propose that it may be a useful progression biomarker or focus of therapeutic intervention for this disease.",
keywords = "miR-24, p27, prostate cancer",
author = "Seodhna Lynch and Michael McKenna and Colum Walsh and Declan McKenna",
year = "2015",
month = "10",
language = "English",
volume = "84",
pages = "208--209",
journal = "Ulster Medical Journal, The",
issn = "0041-6193",
number = "3",

}

miR-24 regulates p27 expression in prostate cancer. / Lynch, Seodhna; McKenna, Michael; Walsh, Colum; McKenna, Declan.

In: Ulster Medical Journal, Vol. 84, No. 3, 10.2015, p. 208-209.

Research output: Contribution to journalArticle

TY - JOUR

T1 - miR-24 regulates p27 expression in prostate cancer

AU - Lynch, Seodhna

AU - McKenna, Michael

AU - Walsh, Colum

AU - McKenna, Declan

PY - 2015/10

Y1 - 2015/10

N2 - MicroRNAs (miRNAs) are small, non-coding RNA molecules with an important role in cancer. In prostate cancer, several miRNAs are expressed abnormally suggesting they may be useful markers for diagnosis, prognosis, and potential therapeutic intervention in this disease. In this study we used PCR to investigate the expression of miR-24 in a panel of prostate cancer cell-lines and in a series of clinical prostate biopsy specimens. The biological significance of miR-24 expression in prostate cancer cells was assessed by a series of in vitro bioassays and the effect on proposed targets p27 (CDKN1B) and p16 (CDK2NA) was investigated. We showed that miR-24 expression was significantly lower in prostate cancer cell lines compared to a normal prostate epithelial cell line. Decreased expression of miR-24 was also more frequently observed in both needle core and prostatectomy tumour tissue relative to matched normal tissue. Low miR-24 expression correlated with high PSA serum levels and other markers of increased prostate cancer progression. Importantly, over-expression of miR-24 inhibited cell cycle, proliferation, migration and clonogenic potential of prostate cancer cells, as well as inducing apoptosis. p27 and p16 were confirmed as targets of miR-24 in prostate cancer cells and a significant inverse correlation between miR-24 and p27 was revealed in clinical prostatectomy specimens. These findings provide evidence that miR-24 has a tumour suppressor role in prostate cancer and also targets p27 and p16 in prostate cancer cells. We propose that it may be a useful progression biomarker or focus of therapeutic intervention for this disease.

AB - MicroRNAs (miRNAs) are small, non-coding RNA molecules with an important role in cancer. In prostate cancer, several miRNAs are expressed abnormally suggesting they may be useful markers for diagnosis, prognosis, and potential therapeutic intervention in this disease. In this study we used PCR to investigate the expression of miR-24 in a panel of prostate cancer cell-lines and in a series of clinical prostate biopsy specimens. The biological significance of miR-24 expression in prostate cancer cells was assessed by a series of in vitro bioassays and the effect on proposed targets p27 (CDKN1B) and p16 (CDK2NA) was investigated. We showed that miR-24 expression was significantly lower in prostate cancer cell lines compared to a normal prostate epithelial cell line. Decreased expression of miR-24 was also more frequently observed in both needle core and prostatectomy tumour tissue relative to matched normal tissue. Low miR-24 expression correlated with high PSA serum levels and other markers of increased prostate cancer progression. Importantly, over-expression of miR-24 inhibited cell cycle, proliferation, migration and clonogenic potential of prostate cancer cells, as well as inducing apoptosis. p27 and p16 were confirmed as targets of miR-24 in prostate cancer cells and a significant inverse correlation between miR-24 and p27 was revealed in clinical prostatectomy specimens. These findings provide evidence that miR-24 has a tumour suppressor role in prostate cancer and also targets p27 and p16 in prostate cancer cells. We propose that it may be a useful progression biomarker or focus of therapeutic intervention for this disease.

KW - miR-24

KW - p27

KW - prostate cancer

M3 - Article

VL - 84

SP - 208

EP - 209

JO - Ulster Medical Journal, The

T2 - Ulster Medical Journal, The

JF - Ulster Medical Journal, The

SN - 0041-6193

IS - 3

ER -